Food Science and Technology Program, BNU-HKBU United International College, Zhuhai, Guangdong 519087, China.
Food Science and Technology Program, BNU-HKBU United International College, Zhuhai, Guangdong 519087, China; Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
Food Res Int. 2021 Nov;149:110664. doi: 10.1016/j.foodres.2021.110664. Epub 2021 Aug 25.
Type 2 diabetes mellitus is a chronic metabolic disorder that tends to disarray various metabolic pathways. Dietary-mediated T2DM prevention garners much attention in recent decades. Hence, this study was intended to elucidate the antidiabetic properties of Konjac glucomannan (KGM) in diabetic rats. Our experimental design includes five groups, with six rats in each group. Group 1 feeding standard diet pallet alone served as control rats; group 2 was KGM control rats administered intragastrically with KGM (120 mg/kg b.w.). Group 3 was developed as diabetic rats with a high-fat diet and an intraperitoneal injection of Streptozotocin-40 mg/kg b.w. Group 4 were diabetic rats treated with KGM (80 mg/kg b.w.), and group 5 were diabetic rats received rosiglitazone treatment (4 mg/kg b.w.). The results showed that STZ-induced diabetic rats significantly elevate liver marker enzymes and gluconeogenesis enzymes. Diminished glycolytic enzymes, liver glycogen, insulin signaling genes, and proteins were also seen in diabetic rats. Treatment with KGM augmented glycolytic enzymes and liver glycogen. On the other hand, KGM diminished gluconeogenesis, liver marker enzymes, upregulated gene, and protein expression of the insulin pathway. The current results suggest dietary KGM can offer a better health benefit in the treatment of T2DM.
2 型糖尿病是一种慢性代谢紊乱疾病，容易扰乱各种代谢途径。近年来，饮食介导的 2 型糖尿病预防受到了广泛关注。因此，本研究旨在阐明魔芋葡甘聚糖（KGM）在糖尿病大鼠中的抗糖尿病特性。我们的实验设计包括五个组，每组有六只大鼠。第 1 组仅喂食标准饮食垫作为对照大鼠；第 2 组为 KGM 对照组大鼠，灌胃给予 KGM（120mg/kg b.w.）。第 3 组为高脂肪饮食和腹腔注射链脲佐菌素-40mg/kg b.w.诱导的糖尿病大鼠组。第 4 组为 KGM（80mg/kg b.w.）治疗的糖尿病大鼠组，第 5 组为罗格列酮治疗的糖尿病大鼠组（4mg/kg b.w.）。结果表明，STZ 诱导的糖尿病大鼠肝脏标志物酶和糖异生酶显著升高。糖尿病大鼠的糖酵解酶、肝糖原、胰岛素信号基因和蛋白也减少。KGM 治疗可增加糖酵解酶和肝糖原。另一方面，KGM 减少糖异生、肝脏标志物酶、上调胰岛素通路的基因和蛋白表达。目前的结果表明，饮食中的 KGM 可以在治疗 2 型糖尿病方面提供更好的健康益处。
